Ascendis Pharma A/S $ASND Shares Sold by Catalio Capital Management LP

Catalio Capital Management LP lowered its position in Ascendis Pharma A/S (NASDAQ:ASND) by 17.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 119,265 shares of the biotechnology company’s stock after selling 25,689 shares during the period. Ascendis Pharma A/S comprises approximately 4.7% of Catalio Capital Management LP’s investment portfolio, making the stock its 6th biggest position. Catalio Capital Management LP’s holdings in Ascendis Pharma A/S were worth $25,432,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the third quarter worth about $26,000. Arax Advisory Partners raised its position in shares of Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $36,000. Global Retirement Partners LLC raised its position in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares during the period. Finally, GW&K Investment Management LLC raised its position in shares of Ascendis Pharma A/S by 75.2% in the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 97 shares during the period.

Insider Activity

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average price of $237.80 per share, with a total value of $95,120.00. Following the purchase, the director owned 400 shares in the company, valued at approximately $95,120. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The disclosure for this sale is available in the SEC filing. 40.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of analyst reports. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Wells Fargo & Company cut their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Royal Bank Of Canada upped their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. Wolfe Research restated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Finally, The Goldman Sachs Group restated a “buy” rating and set a $255.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Stock Down 0.0%

ASND opened at $231.15 on Thursday. Ascendis Pharma A/S has a twelve month low of $160.86 and a twelve month high of $250.74. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average price of $232.16 and a 200 day moving average price of $224.09. The company has a market cap of $14.42 billion, a PE ratio of 26.66 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. Sell-side analysts expect that Ascendis Pharma A/S will post 14.25 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.